Pramipexole-d7-1 (dihydrochloride)

Pramipexole-d7-1 (dihydrochloride)

• CAS Number: 2702798-58-9
• UNSPSC Description: Pramipexole-d7-1 (dihydrochloride) is the deuterium labeled Pramipexole dihydrochloride[1]. Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS)[2][3][4].
• Target Antigen: Dopamine Receptor
• Type: Isotope-Labeled Compounds
• Related Pathways: GPCR/G Protein;Neuronal Signaling
• Applications: Neuroscience-Neuromodulation
• Field of Research: Neurological Disease
• Solubility: 10 mM in DMSO
• Smiles: NC1=NC2=C(S1)C[C@H](CC2)NC([2H])([2H])C([2H])([2H])C([2H])([2H])[2H].Cl
• Molecular Weight: 254.83
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.|[2]Kvernmo, T., et al. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther, 2006. 28(8): p. 1065-78.|[3]Takashi Okura, et al. Blood-brain barrier transport of pramipexole, a dopamine D2 agonist. Life Sci. 2007 Apr 380(17):1564-71.|[4]Ginetta Collo, et al. Ropinirole and Pramipexole Promote Structural Plasticity in Human iPSC-Derived Dopaminergic Neurons via BDNF and mTOR Signaling. Neural Plast. 2018 2018: 4196961.|[5]Ginetta Collo, et al. Ropinirole and Pramipexole Promote Structural Plasticity in Human iPSC-Derived Dopaminergic Neurons via BDNF and mTOR Signaling. Neural Plast. 2018 2018: 4196961.P M Carvey, et al. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J Neural Transm (Vienna). 1997104(2-3):209-28.|[6]Syed Suhail Andrabi, et al. Pramipexole prevents ischemic cell death via mitochondrial pathways in ischemic stroke. Dis Model Mech. 2019 Aug 1 12(8): dmm033860.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported